AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04183452
Drug: 17-Hydroxyprogesterone Caproate 275 mg SC Dose
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Trial: NCT02753166
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
Trial: NCT02452307
Drug: Montanide ISA-51
RxNorm normalized name: isopropyl alcohol
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous
Trial: NCT02452307
Drug: Granulocyte macrophage colony stimulating factor (GM-CSF)
RxNorm normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intradermal
Trial: NCT02452307
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: epicutaneous
Trial: NCT02452307
Drug: mRNA
RxNorm normalized name: mRNA-3705
DrugBank: SARS-CoV-2 mRNA vaccine (DB15855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous
Trial: NCT02452307
Drug: Protamin
RxNorm normalized name: Protamina
DrugBank: Protamine sulfate (DB09141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous
Trial: NCT01602224
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01602224
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SQ
Trial: NCT00670553
Drug: panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01989455
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)
Trial: NCT03966898
Drug: SHR6390 Tablets
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6390 Tablets
Trial: NCT03966898
Drug: Letrozole or Anastrozole Tablets
RxNorm normalized name: Anastrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole or Anastrozole Tablets
Trial: NCT02059616
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral administration for 8 weeks
Trial: NCT02059616
Drug: Amlodipine 10mg
RxNorm normalized name: AMLODIPINE 10MG/VALSARTAN 160MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral administration for 8 weeks
Trial: NCT02059616
Drug: Candesartan Cilexetil 8mg
RxNorm normalized name: CANDESARTAN CILEXETIL 8MG TAB
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily oral administration for 8 weeks
Trial: NCT02059616
Drug: Candesartan cilexetil 16mg
RxNorm normalized name: CANDESARTAN CILEXETIL 16MG TAB
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily oral administration for 8 weeks
Trial: NCT00980473
Drug: Travatan/ Timolol/Azopt
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00632203
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
Trial: NCT01579968
Drug: eptacog alfa (activated)
RxNorm normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
Trial: NCT01832051
Drug: 89Zr-trastuzumab injection
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00440102
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine
Trial: NCT00774761
Drug: fluticasone propionate/formoterol fumarate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: inhalation suspension
Trial: NCT00440102
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate
Trial: NCT00774761
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: inhalation suspension
Trial: NCT00774761
Drug: formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: inhalation solution
Trial: NCT02099292
Drug: Rituximab and DexaBEAM
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: combination treatment
Trial: NCT01917136
Drug: 11C-acetate
RxNorm normalized name: 11C-ACETATE
DrugBank: Acetic acid C-11 (DB15111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
Trial: NCT01917136
Drug: [18F]Fluoro-2-deoxy-2-D-glucose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
Trial: NCT04532268
Drug: Humanized CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive humanized CD19 CAR T-cells by intravenous infusion
Trial: NCT01131988
Drug: Tacrolimus Capsules
RxNorm normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
Trial: NCT02217839
Drug: DG3173+Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02217839
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02217839
Drug: DG3173 Placebo+Octreotide Placebo
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02217839
Drug: Octreotide+DG3173 Placebo
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01962792
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01962792
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01962792
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04452318
Drug: REGN10933 + REGN10987
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) or Intramuscular (IM) injections
Trial: NCT03989024
Drug: Gonadorelin
RxNorm normalized name: Gonadorelin
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
Trial: NCT03989024
Drug: Clomiphene
RxNorm normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
Trial: NCT00198146
Drug: Zenapax
RxNorm normalized name: Zenapax
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02387242
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of rifampicin
Trial: NCT03928522
Drug: hand mixed vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hand mixed vancomycin powder into cement
Trial: NCT00005623
Drug: cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04862715
Drug: Ferinject
RxNorm normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited
Trial: NCT01319669
Drug: recombinant human thrombopoietin
RxNorm normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human thrombopoietin injection in 15000U/ml/amp.
Trial: NCT01649895
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
Trial: NCT04277949
Drug: UV endonuclease from Micrococcus luteus
RxNorm normalized name: Micrococcus luteus preparation
DrugBank: DONU (DB12968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of topical DNA repair enzymes
Trial: NCT02554786
Drug: Indacaterol acetate/Mometasone furoate
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554786
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02554786
Drug: Salmeterol xinafoate/fluticasone propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00090623
Drug: rhuFab V2 (ranibizumab)
RxNorm normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02221570
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
Trial: NCT04458311
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Supplied as 125 mg tablets
Trial: NCT02620501
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical lidocaine
Trial: NCT02918617
Drug: Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3
RxNorm normalized name: potassium nitrate Toothpaste
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03577275
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator with known effect on QT interval
Trial: NCT02148185
Drug: MT-1303
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04458311
Drug: Tildrakizumab
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
Trial: NCT00002682
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002682
Drug: Bismuth Subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002682
Drug: Metronidazole Hydrochloride
RxNorm normalized name: metronidazole hydrochloride
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002682
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03346434
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection, subcutaneous (SC)
Trial: NCT00297310
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00723086
Drug: docetaxel (XRP6976)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combined treatment with prednisolone
Trial: NCT01714336
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
Trial: NCT02773524
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
Trial: NCT01943136
Drug: papaya 1% extract ointment
DrugBank: Papaya (DB10658)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01943136
Drug: mupirocin 2% ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02202161
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
Trial: NCT02202161
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Trial: NCT03580135
Drug: Propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
Trial: NCT03580135
Drug: Mineral Trioxide Aggregate
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
Trial: NCT00002697
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002697
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002697
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01830829
Drug: Jalyn
RxNorm normalized name: Jalyn
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study drug
Trial: NCT00231491
Drug: Botulinum Toxin A (Botox )
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT02885636
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose
Trial: NCT03544385
Drug: Ringers Solution
RxNorm normalized name: ringers solution,acetated
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment vs Placebo
Trial: NCT03737123
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 4 IV Day 1 of each 21 day cycle
Trial: NCT03737123
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
Trial: NCT03737123
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
Trial: NCT00665340
Drug: Levitra (Vardenafil, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5m, 10 mg and 20 mg 1 h prior to sexual intercourse
Trial: NCT03371004
Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
RxNorm normalized name: 4-demethyl-4-cholesteryloxycarbonylpenclomedine
DrugBank: Mipicoledine (DB15075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration as described
Trial: NCT03737123
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
Trial: NCT00383552
Drug: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
Trial: NCT00383552
Drug: Mometasone Furoate MDI (MF MDI)
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MF 100 mcg via metered dose inhaler twice daily for 26 weeks
Trial: NCT00383552
Drug: Formoterol Fumarate 10 mcg
RxNorm normalized name: formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: F via metered dose inhaler 10 mcg twice a day for 26 weeks
Trial: NCT01842334
Drug: Nicotine Replacement Therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NRT administered to both DCS and placebo group.
Trial: NCT01738724
Drug: Dienogest
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest 2mg pills daily during 6 months
Trial: NCT01738724
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
Trial: NCT01738724
Drug: Desogestrel
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desogestrel 75mcg pills daily during six months
Trial: NCT00191438
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191438
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01688479
Drug: Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696774
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.
Trial: NCT02074436
Drug: EACA
RxNorm normalized name: EACA
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.